With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit.  | Rocket ...

Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential ...

While OCU410’s efficacy was not as strong as it was in a preliminary analysis, analysts still foresee the drug carving a ...

All six participants tolerated surgical and intra-cochlear SENS-501 administration well, with no serious adverse events ...

Ocugen’s updated fair value estimate has shifted from US$10.36 to US$11.57, putting recent analyst work into a slightly higher price target range. Analysts are tying this move to fresh research around ...

Rocket Pharmaceuticals recently announced that the U.S. FDA has granted accelerated approval for KRESLADI (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy for ...

As we continue our series exploring genetic medicine, both in this story and in Destiny's Child No Longer: Rewriting Genetic Fate, gene therapy stands at a crossroads. On June 16, Sarepta Therapeutics ...

With promise to slow aging and cure some types of cancer, a new gene therapy presents cost and access hurdles for CT patients ...

An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and ...

The post HYD Pioneers New Research Revealing Systemic Role of Deuterium-Depleted Water in Cancer Therapy appeared first on ...

While gene therapy for cystic fibrosis is still in the research phase, researchers aim to correct the defective gene responsible for the disease. Current research is promising. Cystic fibrosis (CF) is ...